Trial · NCT02603172
Participant flow72
How many started, completed or left each group, period by period.
1 to 20 of 72
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A (Approximately 16 Weeks) | STARTED | GSK3039294 200 mg + GSK3039294 600 mg | 7 | |
| Part A (Approximately 16 Weeks) | STARTED | GSK3039294 200 mg + GSK3039294 600 mg/GSK3039294 600 mg QD | 1 | |
| Part A (Approximately 16 Weeks) | STARTED | GSK3039294 600 mg +GSK3039294 1200 mg | 8 | |
| Part A (Approximately 16 Weeks) | STARTED | GSK3039294 600 mg +GSK3039294 1200 mg/GSK3039294 600 mg QD | 1 | |
| Part A (Approximately 16 Weeks) | STARTED | GSK3039294 600 mg QD | 0 | |
| Part A (Approximately 16 Weeks) | STARTED | GSK3039294 (Cohort 4a) | 0 | |
| Part A (Approximately 16 Weeks) | STARTED | GSK3039294 (Cohort 4b) | 0 | |
| Part A (Approximately 16 Weeks) | STARTED | Part C: GSK3039294 | 0 | |
| Part A (Approximately 16 Weeks) | COMPLETED | GSK3039294 200 mg + GSK3039294 600 mg | 7 | |
| Part A (Approximately 16 Weeks) | COMPLETED | GSK3039294 200 mg + GSK3039294 600 mg/GSK3039294 600 mg QD | 1 | |
| Part A (Approximately 16 Weeks) | COMPLETED | GSK3039294 600 mg +GSK3039294 1200 mg | 7 | |
| Part A (Approximately 16 Weeks) | COMPLETED | GSK3039294 600 mg +GSK3039294 1200 mg/GSK3039294 600 mg QD | 1 | |
| Part A (Approximately 16 Weeks) | COMPLETED | GSK3039294 600 mg QD | 0 | |
| Part A (Approximately 16 Weeks) | COMPLETED | GSK3039294 (Cohort 4a) | 0 | |
| Part A (Approximately 16 Weeks) | COMPLETED | GSK3039294 (Cohort 4b) | 0 | |
| Part A (Approximately 16 Weeks) | COMPLETED | Part C: GSK3039294 | 0 | |
| Part A (Approximately 16 Weeks) | NOT COMPLETED | GSK3039294 200 mg + GSK3039294 600 mg | 0 | |
| Part A (Approximately 16 Weeks) | NOT COMPLETED | GSK3039294 200 mg + GSK3039294 600 mg/GSK3039294 600 mg QD | 0 | |
| Part A (Approximately 16 Weeks) | NOT COMPLETED | GSK3039294 600 mg +GSK3039294 1200 mg | 1 | |
| Part A (Approximately 16 Weeks) | NOT COMPLETED | GSK3039294 600 mg +GSK3039294 1200 mg/GSK3039294 600 mg QD | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02603172/flow